These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 11729475)

  • 1. [Neoadjuvant chemotherapy for advanced epithelial ovarian cancer].
    Hatae M; Onishi Y; Nakamura T; Yamamoto H; Kusumoto M; Matsui T; Mihara K; Taniguchi H
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1833-7. PubMed ID: 11729475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neoadjuvant chemotherapy and ovarian cancer].
    Ray-Coquard I; Saba C; Bachelot T; Méeus P; Mignotte H; Blondet R; Treilleux I; Peix M; Guastalla JP
    Bull Cancer; 2006 Jul; 93(7):669-76. PubMed ID: 16873075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer.
    Vergote IB; De Wever I; Decloedt J; Tjalma W; Van Gramberen M; van Dam P
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):31-6. PubMed ID: 10952124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
    Vergote I; Amant F; Kristensen G; Ehlen T; Reed NS; Casado A
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S88-92. PubMed ID: 21944035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neo-adjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer treatment--a retrospective study].
    Tkácová M; Vertaková-Krakovská B; Belohorská B; Miskovská V; Helpianska L; Ondrus D; Ondrusová M; Spánik S; Svec J
    Klin Onkol; 2009; 22(6):273-7. PubMed ID: 20099745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.
    Lee SJ; Kim BG; Lee JW; Park CS; Lee JH; Bae DS
    J Obstet Gynaecol Res; 2006 Feb; 32(1):99-106. PubMed ID: 16445534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.
    Hou JY; Kelly MG; Yu H; McAlpine JN; Azodi M; Rutherford TJ; Schwartz PE
    Gynecol Oncol; 2007 Apr; 105(1):211-7. PubMed ID: 17239941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy for advanced ovarian cancer.
    Schwartz PE; Chambers JT; Makuch R
    Gynecol Oncol; 1994 Apr; 53(1):33-7. PubMed ID: 8175019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy in ovarian cancer.
    Park TW; Kuhn WC
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):639-47. PubMed ID: 15270667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ovarian cancer].
    Onda T
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1735-9. PubMed ID: 18030006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The position of neoadjuvant chemotherapy within the treatment of ovarian cancer.
    Van Gorp T; Amant F; Neven P; Berteloot P; Leunen K; Vergote I
    Minerva Ginecol; 2006 Oct; 58(5):393-403. PubMed ID: 17006426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and management of epithelial ovarian cancer.
    Bhoola S; Hoskins WJ
    Obstet Gynecol; 2006 Jun; 107(6):1399-410. PubMed ID: 16738170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Up-date on cytoreductive surgery in the management of advanced ovarian cancer].
    Angioli R; Palaia I; Damiani P; Montera R; Benedetti Panici P
    Minerva Ginecol; 2006 Dec; 58(6):459-70. PubMed ID: 17108876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Le T; Hopkins L; Faught W; Fung-Kee-Fung M
    Gynecol Oncol; 2007 Jun; 105(3):712-5. PubMed ID: 17400284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer.
    Lim MC; Song YJ; Seo SS; Yoo CW; Kang S; Park SY
    Onkologie; 2010; 33(6):324-30. PubMed ID: 20523098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Latest information in the diagnoses of ovarian carcinoma].
    Isonishi S
    Gan To Kagaku Ryoho; 2002 Aug; 29(8):1351-7. PubMed ID: 12214460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Du Bois A;
    Gynecol Oncol; 2007 Jul; 106(1):69-74. PubMed ID: 17397910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Le T; Alshaikh G; Hopkins L; Faught W; Fung MF
    Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.
    Bristow RE; Chi DS
    Gynecol Oncol; 2006 Dec; 103(3):1070-6. PubMed ID: 16875720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer.
    Morice P; Dubernard G; Rey A; Atallah D; Pautier P; Pomel C; Lhommé C; Duvillard P; Castaigne D
    J Am Coll Surg; 2003 Dec; 197(6):955-63. PubMed ID: 14644284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.